1Vidt DG.lnflammation in renal disease.Am J Cardi01.2006,97(2A).20A-27A.
2Liu F,Brezniceanu ML Wei CC,et al.Overexpression of angiotensin0gen in- creases tubular apoptosis in diabetes.J Am Soc Nephrol, 2008,19(2):269-280.
3Siragy HM.Xue C.Local renal aldosterone production induces inflammation and matrix formation in Kidneys of diabetie rats.Exp Physi01.2008,93 (7):817- 824,.
4Mogensen CE.Early diabetic renal involvement and nephropathy.In: Alberti DGMM, Krall LP, The Diabtes Ann(Vol3),Amsterdam,Elsevier Science Publishers, 1987:306.
5Fouque D,Aparicio M.Eleven reasons to control the proten intakeof patients with chronic kidney disease[J].Nat.Clin Pratt Nephrol, 2007,3:383-392.
1Parving HH. Initiation and progression of diabetic nephropathy. N Engl J Med, 1996,335 : 1682-1683.
2Gareia-Donaire JA, Segura J, Ruilope LM. An update of irbesartan and renin-anglotensin system blockade in diabetic nephropahy. Expert Opin Pharmacother, 2005,6 : 1587-1596.
3Sasso FC, Carbonara O, Persico M, et al. Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension. Diabetes Care, 2002,25 : 1909-1913.
4Rossing K, Schjoedt K J, Jensen BR, et al. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int, 2005,68 : 1190-1198.
5Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med, 2001,345,870-878.
6Mathiesen ER, Hommel E, Hansen HP, et al. Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria. BMJ, 1999,319:24-25.
7Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Lancet, 2000,355:253-259.
8The ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? Ann Intern Med, 2001,134 : 370.
9Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med, 2001,345:851- 860.
10Agardh CD, Garcia-Puig J, Charbonnel B, et al. Greater reduction of urinary albumin excretion in hypertensive type Ⅱ diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J Hum Hypertens, 1996 ,10 :185-192.
